ELI LILLY AND COMPANY Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
ELI LILLY AND COMPANY (LLY) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $435.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2025-02-19
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2022-03-31 was $108.10M, a 0.00% change year-over-year.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-12-31 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-09-30 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2021-06-30 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $435.00M.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $108.10M.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2014 was $0.00.
- ELI LILLY AND COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month as first filed | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $435.00M 10-K · filed 2025-02-19 | ||||
| 2022-03-31 | $108.10M 10-Q · filed 2022-04-29 | $108.10M derived: sum of 2 quarters · filed 2024-02-21 | $108.10M derived: sum of 3 quarters · filed 2024-02-21 | $108.10M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $108.10M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $108.10M 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $108.10M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $108.10M 10-Q · filed 2021-04-30 | ||||
| 2017-12-31 | $50.00M 8-K · filed 2019-10-24 | ||||
| 2014-12-31 | $0.00 10-K · filed 2015-02-19 | ||||
| 2013-12-31 | $0.00 10-K · filed 2015-02-19 | ||||
| 2012-12-31 | $221.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $205.00M 10-K · filed 2015-02-19 | |||
| 2012-09-30 | -$16.00M 10-Q · filed 2012-10-26 | ||||
| 2011-12-31 | $302.50M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $151.50M 10-K · filed 2014-02-19 | |||
| 2011-09-30 | -$151.00M 10-Q · filed 2012-10-26 | $151.00M 10-Q · filed 2011-10-28 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $0.00 10-K · filed 2013-02-21 | |||
| 2010-09-30 | $0.00 10-Q · filed 2011-10-28 | ||||
| 2009-12-31 | $0.00 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |